The herbal anxiolytics kava and valerian for anxiety and insomnia

Psychiatric Annals

Volumn 32, Issue 1, 2002, Pages 55-60

  Mischoulon, David ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; FLUNITRAZEPAM; HERBACEOUS AGENT; KAVA; KAWAIN; PROPRANOLOL; VALERIAN;

ACUTE HEPATITIS; ANOREXIA; ANXIETY DISORDER; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; DYSTONIA; EYE DISEASE; EYE REDNESS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HERBAL MEDICINE; HUMAN; INSOMNIA; JAUNDICE; LIVER TOXICITY; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN ALLERGY; SKIN DISEASE; TERATOGENICITY; VERTIGO; VISUAL DISORDER; VISUAL IMPAIRMENT;

EID: 0036114769     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020101-09     Document Type: Review

References (51)

1. Mischoulon D, Rosenbaum JF. The use of natural remedies in psychiatry: a commentary. Har Rev Psychiatry. 1999;6:279-283.
2. Singh YN. Kava: an overview. J Ethnopharmacol. 1992;37:13-45.
3. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine, 4th ed. Berlin: Springer; 2001.
4. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30:1-5.
5. Kinzler E, Kromer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis: double blind study with placebos over 4 weeks. Arzneimettel-Forschung. 1991;41:584-588.
6. Warnecke G. Psychosomatic dysfunctions in the female climacteric: clinical effectiveness and tolerance of Kava Extract WS 1490. Fortschritte der Medizin. 1991;109:119-122.
7. Seitz U, Ameri A, Pelzer H, Gleitz J, Peters T. Relaxation of evoked contractile activity of isolated guinea-pig ileum by (+/-)-kavain. Planta Med. 1997;63:303-306.
8. Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. J Ethnopharmacol. 1983;7:267-276.
9. Gleitz J, Friese J, Beile A, Ameri A, Peters T. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol. 1996;315:89-97.
10. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol. 1991;18:571-578.
11. Laux G. Pharmacotherapy [in German]. Ther Umsch. 1997;54:595-599.
12. Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol. 1990;17:495-507.
13. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl). 1994;116:469-474.
14. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol. 1992;71:120-126.
15. Holm E, Staedt U, Heep J, et al. The action profile of D,L-kavain: cerebral sites and sleep-wakefulness-rhythm in animals [in German]. Arzneimettel-Forschung. 1991;41:673-683.
16. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997;63:548-549.
17. Walden J, von Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Progress in Neuropsychopharmacology and Biological Psychiatry. 1997;21:697-706.
18. Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol. 1992;215:265-269.
19. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31:187-192.
20. Suss R, Lehmann P. Hematogenous contact eczema caused by phytogenic drugs exemplified by kava root extract [in German]. Hautarzt. 1996;47:459-461.
21. Hansel R, Keller K, Rimpler H, Schneider G, eds. Hagers Handbuch der Pharmazeutischen Praxis, 6th ed. New York: Springer Verlag; 1994:201-221, 268-292.
22. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. Deutsche Medizinische Wochenschrift. 1998;123:1410-1414.
23. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200-2211.
24. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940-941. Letter.
25. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol. 1990;17:509-514.
26. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol. 1994;31:89-97.
27. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an Aboriginal community. Med J Aust. 1988;148:548-555.
28. Houghton PJ. The biological activity of Valerian and related plants. J Ethnopharmacol. 1988;22:121-142.
29. Cott JM. Natural product formulations available in Europe for psychotropic indications. Psychopharmacology Bulletin. 1995;273:607-609.
30. Comas-Diaz L. Culturally relevant issues and treatment implications for Hispanics. In: Koslow DR, Salett EP, eds. Crossing Cultures in Mental Health. Washington, DC: SIETAR International; 1989:31-48.
31. Hendriks H, Bos R, Woerdenbag HJ, Koster AS. Central nervous system depressant activity of valerennic acid in the mouse. Planta Med. 1985;51:28-3l.
32. Leuschner J, Muller J, Rudmann M. Characterization of the central nervous depressant activity of a commercially available valerian root extract. Arzneimettel-Forschung. 1993;43:638-641.
33. Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985;87:406-409.
34. Gessner B, Klassner M. The effect of harmonicum on human sleep: a polygraphic EEG investigation. EEG-EMG: Zeitschrift fur Elektroenzephalographie Elektromyographie und Verwandte Gebiete. 1984;15:45-51.
35. Schultz H, Jobert M. Die Darstellung sedierender/tranquilisierender Wirkungen von Phytopharmaka im quantifizierten EEG. Zeitung Phytotherapy Abstractband. 1995;10. Abstract.
36. Riedel E, Hansel R, Ehrke G. Hemmung des Gamma-Aminobuttersaureabbaus durch Valerensaurederivate. Planta Med. 1982;46:219-220.
37. Santos MS, Ferreira F, Cunha AP, Carvalho AP, Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med. 1994;60:278-279.
38. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17:65-71.
39. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 1985;2:144-148.
40. Vorbach EU, Gortelmayer R, Brunning J. Therapie von Insomnien: Wirksamkeit and Vertraglichkeit eines Baldrian-Preparates. Psychopharmakotherapie. 1996;3:109-115.
41. Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry. 1988;21:447-448.
42. Gerhard U, Linnenbrink N, Georghiadou CH, et al. Effects of two plant-based sleep remedies on vigilance. Schweizerische Rundschau fur Medizin. 1996;85:473-481.
43. Schmitz M, Jackel M. Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug [in German]. Wien Med Wochenschr. 1998;148:291-298.
44. Lindahl O, Lindwall L. Double-blind study of a valerian preparation. Pharmacol Biochem Behav. 1989;32:1065-1066.
45. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol. 1995;37:364-365.
46. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998;280:1566-1567. Letter.
47. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicity of herbal medicines. BMJ. 1989;299:1156-1157.
48. Chan TY, Tang CH, Critchley JA. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian). Postgrad Med J. 1995;71:227-228.
49. Farrell RJ, Lamb J. Herbal remedies. BMJ. 1990;300:47-48.
50. Braun R, Dittmar W, Machut M, et al. Valepotriate mit Epoxidstruktur-beachtliche Alkylantien. Deutsche Apotheker Zeitung. 1982;122:1109-1113.
51. Braun R, Dittmar W, vonder Hude W, et al. Bacterial mutagenicity of the tranquilizing constituents of valerianaceae roots. Naunyn-Schmiedeberg's Archives of Pharmacology Supplement. 1985;329:R28.